About Roxro Pharma
Roxro Pharma is a company based in Menlo Park (United States) founded in 1999 was acquired by Luitpold in December 2010.. Roxro Pharma has raised $42.7 million across 1 funding round from investors including Thomas Weisel Partners, Luitpold and Prospect Venture Partners. Roxro Pharma operates in a competitive market with competitors including Flexion Therapeutics, Eliem Therapeutics, Zogenix, Heron Therapeutics and Ethypharm, among others.
- Headquarter Menlo Park, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Roxro Pharma Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$42.7 M (USD)
in 1 rounds
-
Latest Funding Round
$42.7 M (USD), Series B
Jun 12, 2007
-
Investors
Thomas Weisel Partners
& 3 more
-
Employee Count
Employee Count
-
Acquired by
Luitpold
(Dec 13, 2010)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Roxro Pharma
Roxro Pharma has successfully raised a total of $42.7M through 1 strategic funding round. The most recent funding activity was a Series B round of $42.7 million completed in June 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series B — $42.7M
-
First Round
First Round
(12 Jun 2007)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2007 | Amount | Series B - Roxro Pharma | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Roxro Pharma
Roxro Pharma has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Thomas Weisel Partners, Luitpold and Prospect Venture Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in US life sciences and healthtech firms.
|
Founded Year | Domain | Location | |
|
VC firm investing in the US
|
Founded Year | Domain | Location | |
|
Wealth management services are provided to high-net-worth clients.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Roxro Pharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Roxro Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Roxro Pharma Comparisons
Competitors of Roxro Pharma
Roxro Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Eliem Therapeutics, Zogenix, Heron Therapeutics and Ethypharm, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| domain | founded_year | HQ Location |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| domain | founded_year | HQ Location |
Drug delivery systems for CNS disorders and pain are developed.
|
|
| domain | founded_year | HQ Location |
Reformulated injectables for chemotherapy side effects and pain are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for pain and addiction treatment are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for pain management are developed with abuse-deterrent designs.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Roxro Pharma
When was Roxro Pharma founded?
Roxro Pharma was founded in 1999 and raised its 1st funding round 8 years after it was founded.
Where is Roxro Pharma located?
Roxro Pharma is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Is Roxro Pharma a funded company?
Roxro Pharma is a funded company, having raised a total of $42.7M across 1 funding round to date. The company's 1st funding round was a Series B of $42.7M, raised on Jun 12, 2007.
What does Roxro Pharma do?
Roxro Pharma develops drugs for pain treatment. The company acquires discarded or failed drugs from other companies and pushes them through clinical development. Roxro obtained FDA approval for SPRIX Nasal Spray, an intranasal formulation for the treatment of dental and postoperative pain. Other products include: ROX-828, a non-opioid and non-triptan intranasal product for the treatment of migraine. The company was acquired by Luitpold Pharmaceuticals, a USA-based subsidiary of Japanese drug major Daiichi Sankyo.
Who are the top competitors of Roxro Pharma?
Roxro Pharma's top competitors include Flexion Therapeutics, Cara Therapeutics and Satsuma Pharmaceuticals.
Who are Roxro Pharma's investors?
Roxro Pharma has 4 investors. Key investors include Thomas Weisel Partners, Luitpold, Prospect Venture Partners, and Sutter Hill Ventures.